IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA: UPDATED EFFICACY AND SAFETY OF THE RESONATE STUDY WITH UP TO FOUR YEARS OF FOLLOW-UP

被引：0

作者：

Moreno, C. ^{[1
]}

Byrd, J. C. ^{[2
]}

Hillmen, P. ^{[3
]}

O'Brien, S. ^{[4
]}

Barrientos, J. C. ^{[5
]}

Reddy, N. M. ^{[6
]}

Coutre, S. ^{[7
]}

Tam, C. S. ^{[8
,9
]}

Mulligan, S. P. ^{[10
]}

Jaeger, U. ^{[11
]}

Barr, P. M. ^{[12
]}

Furman, R. R. ^{[13
]}

Kipps, T. J. ^{[14
]}

Thornton, P. ^{[15
]}

Montillo, M. ^{[16
]}

Pagel, J. M. ^{[17
]}

Burger, J. A. ^{[18
]}

Jones, J. ^{[2
]}

Dai, S. ^{[19
]}

Vezan, R. ^{[19
]}

James, D. F. ^{[19
]}

Brown, J. R. ^{[20
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[3] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England

[4] Univ Calif Irvine, Irvine, CA USA

[5] Hofstra Northwell Sch Med, Hempstead, NY USA

[6] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[7] Stanford Univ, Sch Med, Stanford, CA USA

[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[9] St Vincents Hosp, Melbourne, Vic, Australia

[10] Royal North Shore Hosp, Sydney, NSW, Australia

[11] Med Univ Vienna, Div Hematol & Hemostaseol, Vienna, Austria

[12] Univ Rochester, Med Ctr, Rochester, NY 14627 USA

[13] Weill Cornell Med Coll, New York, NY USA

[14] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[15] Beaumont Hosp, Dublin, Ireland

[16] Osped Niguarda Ca Granda, Niguarda Canc Ctr, Milan, Italy

[17] Swedish Canc Inst, Hematol Malignancies Program, Seattle, WA USA

[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[19] Pharmacyclics LLC, Sunnyvale, CA USA

[20] Dana Farber Canc Inst, CLL Ctr, Boston, MA 02115 USA

来源：

HAEMATOLOGICA | 2017年 / 102卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S769

引用

页码：311 / 311

页数：1

共 50 条

[21] Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study
Itsara, Andy
Sun, Clare
Bryer, Emily
Ahn, Inhye E.
Soto, Susan
Wang, Hao-Wei
Yuan, Constance M.
Wiestner, Adrian
BLOOD, 2023, 142
[22] IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY
Fraser, G.
Cramer, P.
Demirkan, F.
Santucci Silva, R.
Grosicki, S.
Janssens, A.
Mayer, J.
Dilhuydy, M. S.
Pylypenko, H.
Loscertales, J.
Goy, A.
Avigdor, A.
Rule, S.
Phelps, C.
Mahler, M.
Salman, M.
Howes, A.
Hallek, M.
HAEMATOLOGICA, 2016, 101 : 150 - 151
[23] Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.
Fraser, Graeme
Cramer, Paula
Demirkan, Fatih
Silva, Rodrigo Santucci
Pylypenko, Halyna
Grosicki, Sebastian
Janssens, Ann
Pristupa, Aleksander
Mayer, Jiri
Dilhuydy, Marie-Sarah
Loscertales, Javier
Goy, Andre
Avigdor, Abraham
Rule, Simon
Phelps, Charles
Mahler, Michelle
Salman, Mariya
Howes, Angela J.
Balasubramanian, Sriram
Chanan-Khan, Asher Alban Akmal
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[24] Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Wang, Michael L.
Blum, Kristie A.
Martin, Peter
Goy, Andre
Auer, Rebecca
Kahl, Brad S.
Jurczak, Wojciech
Advani, Ranjana H.
Romaguera, Jorge E.
Williams, Michael E.
Barrientos, Jacqueline C.
Chmielowska, Ewa
Radford, John
Stilgenbauer, Stephan
Dreyling, Martin
Jedrzejczak, Wieslaw Wiktor
Johnson, Peter
Spurgeon, Stephen E.
Zhang, Liang
Baher, Linda
Cheng, Mei
Lee, Dana
Beaupre, Darrin M.
Rule, Simon
BLOOD, 2015, 126 (06) : 739 - 745
[25] Heart transplantation and chronic lymphocytic leukemia: A successful case at 2 years of follow-up
Manito, N
Kaplinsky, E
Roca, J
de Sevilla, AF
Castells, E
Esplugas, E
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2004, 23 (06): : 777 - 779
[26] LONG-TERM EFFICACY AND SAFETY IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN THE RESONATE STUDY: ONCOLOGY NURSE EXPERIENCE IN MANAGEMENT OF ADVERSE EVENTS
Greenberg, Edythe M.
Doehler, Jocelyn E.
Dai, Sandra
Reddy, Vijay
Barr, Paul M.
Burger, Jan A.
ONCOLOGY NURSING FORUM, 2018, 45 (02)
[27] Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison
Andrasiak, Iga
Rybka, Justyna
Knopinska-Posluszny, Wanda
Wrobel, Tomasz
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (05): : 268 - 273
[28] Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
Barr, Paul M.
Robak, Tadeusz
Owen, Carolyn
Tedeschi, Alessandra
Bairey, Osnat
Bartlett, Nancy L.
Burger, Jan A.
Hillmen, Peter
Coutre, Steven
Devereux, Stephen
Grosicki, Sebastian
McCarthy, Helen
Li, Jianyong
Simpson, David
Offner, Fritz
Moreno, Carol
Zhou, Cathy
Styles, Lori
James, Danelle
Kipps, Thomas J.
Ghia, Paolo
HAEMATOLOGICA, 2018, 103 (09) : 1502 - 1510
[29] Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study
Janssens A.
Berneman Z.N.
Offner F.
Snauwaert S.
Mineur P.
Vanstraelen G.
Meers S.
Spoormans I.
Bron D.
Vande Broek I.
Van Bogaert C.
De Beleyr B.
Smet A.
Nielsen L.
Wapenaar R.
André M.
Clinical Hematology International, 2022, 4 (4) : 133 - 143
[30] Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia
Rogers, Kerry A.
Huang, Ying
Ruppert, Amy S.
Abruzzo, Lynne V.
Bhat, Seema A.
Hoffman, Corinne
Maddocks, Kami J.
Lozanski, Gerard
Kittai, Adam S.
Moran, Mollie E.
Reid, Mark
Woyach, Jennifer A.
Byrd, John C.
BLOOD, 2020, 136

← 1 2 3 4 5 →